BofA analyst Kevin Fischbeck raised the firm’s price target on Humana (HUM) to $330 from $312 and keeps a Neutral rating on the shares. The firm views UnitedHealth’s (UNH) Medicare Advantage stars data yesterday as positive for investor sentiment in the managed care group. As a result, BofA is assigning a higher peer multiple for Humana shares. However, an uncertain 2027 Medicare Advantage rate outlook could delay am earnings rebound, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Raymond James says pullback in Humana shares creates buying opportunity
- UnitedHealth Stock (UNH) Leads Health Insurer Rally, Humana (HUM) Drops
- Court approves CenterWell’s winning bid to acquire assets of The Villages Health
- Managed Care 2026 Star plan cut points look ‘challenged,’ says Leerink
- Another ‘hard year’ for Stars cut points, Hyperlift’s Phillip Collins says